{
  "documentMetadata": {
    "title": "Osteomyelitis, Staph. aureus",
    "lastUpdated": "2024-04-12",
    "sourceFile": "Osteomyelitis, Staph. aureus.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Specific therapy for Staphylococcus aureus osteomyelitis. Culture and in vitro susceptibility results are known.",
        "Also see vertebral osteomyelitis."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Methicillin-susceptible Staphylococcus aureus (MSSA)",
        "Methicillin-resistant Staphylococcus aureus (MRSA)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MSSA:"
        },
        {
          "type": "list",
          "items": [
            "Nafcillin 2 gm IV q4h OR Oxacillin 2 gm IV q4h OR Cefazolin 2 gm IV q8h (consider adding Rifampin 300-450 mg IV/po bid to lessen relapse rate [Open Forum Infect Dis. 2022 Jul 27;9(8):ofac366])"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MRSA (see Antimicrobial Stewardship concerning duration):"
        },
        {
          "type": "list",
          "items": [
            "Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) ± Rifampin 300-450 mg IV/po bid (editors prefer the combination whenever possible to lessen relapse rate)"
          ]
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MSSA (beta-lactam hypersensitivity or adverse events)"
        },
        {
          "type": "list",
          "items": [
            "Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) ± Rifampin 300-450 mg IV/po bid",
            "Daptomycin 8-10 mg/kg IV q24h"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MRSA (see Antimicrobial Stewardship concerning duration):"
        },
        {
          "type": "list",
          "items": [
            "Daptomycin 8-10 mg/kg IV q24h ± Rifampin 300-450 mg IV/po bid (editors prefer the combination whenever possible to lessen relapse rate)"
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Oral step-down regimens (in vitro sensitivity known)"
        },
        {
          "type": "list",
          "items": [
            "TMP-SMX 8-10 mg/kg/d po div q8h + Rifampin 600 mg once daily po (Antimicrob Agents Chemother 53:2672, 2009)",
            "(Ciprofloxacin 750 mg po bid or Levofloxacin 750 mg po q24h) + Rifampin 300-450 mg po bid"
          ]
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy is ill-defined but 6-8 weeks seems effective for acute infection",
        "IDSA treatment guidelines: Clin Infect Dis 2015;61:e26.",
        "Verterbral osteomyelitis caused by MRSA, associated with undrained pyogenic complications and extension, or end-stage renal disease has a higher recurrence rate if treated for < 8 weeks (Clin Infect Dis 2016; 62:1262) and > 8 weeks of therapy is recommended.",
        "Longer duration of symptoms before diagnosis and infection with S. aureus also are risk factors for treatment failure (Open Forum Infect Dis 2014; 1:ofu107).",
        "6 weeks of IV/po therapy as efficacious as 12 weeks (see Lancet 385:875, 2015 for details) provided that epidural or paravertebral abscesses can be drained; consider longer course in those with extensive infection or abscess particularly if not amenable to drainage because of increased risk of treatment failure.",
        "> 8 weeks in patients undergoing device implantation (Clin Infect Dis 60:1330, 2015)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "References",
        "General reviews: Infect Dis Clin North Am. 2017;31:325 and Clin Microbiol Rev. 2018;14;31.",
        "Review of drug penetration into bone: J Clin Pharm Ther 38:89, 2013.",
        "Review of oral therapy: Antibiotics (Basel). 2024; 13:4.",
        "Surgical drainage of associated soft tissue abscesses and debridement of necrotic bone is the mainstay of therapy.",
        "Other treatment options when in vitro susceptibility is known but patient has allergy or toxicity issues:",
        "Clindamycin 600–900 mg IV q8h or 300-450 mg po q6-8h",
        "Linezolid 600 mg po/IV bid (issues with hematologic or neurotoxicity for durations of therapy > 2-3 weeks)",
        "Fusidic acidNUS 500 mg IV q8h + Rifampin 300 mg po bid",
        "Ceftriaxone 2 gm IV q24h for an average duration of therapy of 42 days (range 27-132 days) showed similar efficacy as oxacillin for MSSA in one small series (Clin Infect Dis 54:585, 2012).",
        "Observational data suggest that Dalbavancin administered as two 1500 mg IV doses one week apart may be effective (Open Forum Infect Dis. 2021; 9:ofab589; J Antimicrob Chemother. 2020;75:2717)."
      ]
    }
  ]
}